- Home
- Equipment
- australasia
- breast cancer
Refine by
Breast Cancer Equipment Supplied In Australasia
10 equipment items found
Manufactured by:Radiopharm Theranostics based inCarlton, AUSTRALIA
Pivalate is the invention of Professor Eric Aboagye of Imperial College London: Pivalate is an 18F-FPIA radiotracer, based on a short chain carbohydrate which utilises the early steps of fatty acid oxidation and is very stable; In comparison to the clinical standard in PET imaging, 18F-FDG in prostate and brain cancers, Pivalate showed superior imaging performance and was equally ...
Manufactured by:INOVIQ Ltd based inNotting Hill, AUSTRALIA
Exosomes are small membrane-enclosed vesicles actively secreted by most cells into biological fluids including serum, plasma, urine, breast milk, and saliva [1]. Studies have found that the analysis of exosome-associated nucleic acids, proteins and/or lipids can indicate the presence of a range of cancers, including pancreatic cancer, colorectal ...
Manufactured by:Biosceptre International Limited based inCambridge, UNITED KINGDOM
nfP2X7 is a tumour-specific form of the P2X7 ligand-gated ion channel, consisting of three identical protein subunits. When exposed to high concentrations of extracellular adenosine triphosphate (ATP), P2X7 forms a channel, driving a range of diverse physiological functions including proliferation and immune cell functions. Under prolonged stimulation, P2X7 can form a membrane pore that’s ...
by:AdAlta Limited based inBundoora, AUSTRALIA
A specific form of lung fibrosis is Idiopathic pulmonary fibrosis (IPF), which is a chronic and ultimately fatal disease, where tissue deep in the lungs becomes scarred, over time, resulting in a progressive decline in lung function and shortness of breath. There is currently no cure for IPF with most people living only three to five years after diagnosis. The rate at which the disease progresses ...
by:Starpharma Holdings Limited based inMelbourne, AUSTRALIA
DEP® docetaxel is an enhanced version of docetaxel (Taxotere®) – widely used for breast, lung & prostate cancer. Docetaxel (Taxotere®) is a commonly used chemotherapy agent despite having multiple US FDA “Black Box” warnings. DEP® docetaxel is a detergent free, aqueous formulation of docetaxel. ...
by:Cirdan Ltd based inLisburn, NORTHERN IRELAND
Dedicated X-ray specimen cabinet designed for surgical and biopsy ...
by:Starpharma Holdings Limited based inMelbourne, AUSTRALIA
DEP® radiotheranostic conjugates have the potential to minimise off-target toxicity, optimise pharmacokinetics and enhance efficacy when used alone or in combination with other therapeutic approaches. The versatility of Starpharma’s DEP® platform means it can be used with a wide range of therapies and types of molecules (e.g., small molecule drugs, peptides, antibodies, ...
Manufactured by:INOVIQ Ltd based inNotting Hill, AUSTRALIA
INOVIQ has three autoantibody tests in development for early detection of ovarian, breast and lung cancers. BARD1 autoantibody tests measure autoantibodies to variant BARD1 proteins in the blood and use a proprietary cancer-specific algorithm to combine these levels into a cancer score that identifies the presence or absence of a ...
Manufactured by:Cenofex Innovations based inPort Kembla, AUSTRALIA
Lymphoedema is a life-long, painful and incurable disease. Linked to a poorly functioning lymphatic system, it is characterised by a painful swelling of a limb or body region. Lymphoedema is most commonly caused by a removal of lymph nodes during cancer treatment. Along with pain and discomfort, it can also lead to infections due to reduced immunity, restricted movement, depression, poor self ...
Manufactured by:INOVIQ Ltd based inNotting Hill, AUSTRALIA
INOVIQ has the exclusive worldwide license for SubB2M - an engineered protein that binds to a unique sugar molecule called Neu5Gc which is only present in human cancers. In initial clinical studies, SubB2M has detected cancers with 100% sensitivity and specificity for mid to late-stage cancers, and >95% specificity and 100% sensitivity for early-stage cancers. There is also evidence that ...